FDA Says Antiseptics Need Testing Or Face Reformulation, Relabeling
This article was originally published in The Rose Sheet
Executive Summary
FDA proposes to amend the OTC antiseptic drug product monograph to require more detailed safety and efficacy tests, pointing to mounting data that shows antibacterial wash products could pose health risks and contribute to increase antibacterial resistance.
You may also be interested in...
‘Vast Majority’ Of Antibac Soaps Need Reformulation Under FDA Final Rule
FDA says the “vast majority” of roughly 2,100 consumer antibacterial soaps on the market contain at least one of 19 antimicrobial ingredients banned from OTC use under new final rule. Industry, which suggests the agency is overstating the rule’s impact, is focused on delivering supporting data for three active ingredients still pending before FDA for GRASE use in the category.
‘Vast Majority’ Of Antibac Soaps Need Reformulation Under FDA Final Rule
FDA says the “vast majority” of roughly 2,100 consumer antibacterial soaps on the market contain at least one of 19 antimicrobial ingredients banned from OTC use under new final rule. Industry, which suggests the agency is overstating the rule’s impact, is focused on delivering supporting data for three active ingredients still pending before FDA for GRASE use in the category.
FDA: ‘Vast Majority’ Of Antibac Soaps Need Reformulation Under Final Rule
FDA/CDER’s Teresa Michele says the “vast majority” of roughly 2,100 consumer antibacterial soaps on the market contain at least one of 19 antimicrobial ingredients banned from OTC use under an FDA final rule. Industry, which suggests the agency is overstating the rule’s impact, is focused on delivering supporting data for three active ingredients still pending before FDA for GRASE use in the category.